<DOC>
	<DOCNO>NCT00698464</DOCNO>
	<brief_summary>The purpose study evaluate effect vary degree hepatic function ( Child-Pugh classification ) pharmacokinetics safety pasireotide s.c. subject .</brief_summary>
	<brief_title>Pharmacokinetics Safety Single Subcutaneous Pasireotide ( SOM230 ) Subjects With Varying Degrees Hepatic Function</brief_title>
	<detailed_description />
	<mesh_term>Alcoholism</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Somatostatin</mesh_term>
	<criteria>Inclusion criterion : Common Inclusion criterion subject : Male female subject 18 75 year age , inclusive . Vital sign screen baseline within normal range . Subjects must BMI 20 kg/m2 30 kg/m2 . Inclusion Criteria cohort 1 : â€¢ Generally healthy subject determine past medical history , physical examination , vital sign , electrocardiogram standard laboratory test screen . Inclusion Criteria cohort 24 : Subjects confirm cirrhosis least one follow criterion : Histologically prior liver biopsy show cirrhosis . Clinically physical examination , and/or laboratory data , and/or liver imaging , and/or endoscopic finding . Exclusion criterion : Common Exclusion criterion subject : Donation loss 400 mL blood within eight week prior dose . Subjects additional active malignant disease within last five year ( exception nonmelanoma skin cancer metastatic treat curatively ) . Subjects abnormal clinical laboratory value ( except clinical laboratory value link hepatic dysfunction ) . Any surgical medical condition may interfere conduct study , may jeopardize subject case participation study may significantly alter absorption , distribution , metabolism excretion drug . History immunocompromise , include positive HIV test result ( ELISA Western blot ) . A HIV test require ; however , previous medical history review Female subject pregnant ( positive pregnancy test screen baseline ) lactating , childbearing potential practicing medically acceptable method birth control . Exclusion Criteria cohort 1 : Clinical evidence liver disease liver injury indicate abnormal liver function test . A positive Hepatitis B surface antigen ( HBsAg ) Hepatitis C test result ( antibody positive subject allow nonviremic ) . Exclusion Criteria cohort 24 : Symptoms history encephalopathy ( Stage III worse ) within three month prior dose . Clinical evidence severe ascites . Exclusion criterion Common Exclusion criterion subject : Donation loss 400 mL blood within eight week prior dose . Subjects additional active malignant disease within last five year ( exception nonmelanoma skin cancer metastatic treat curatively ) . Subjects abnormal clinical laboratory value ( except clinical laboratory value link hepatic dysfunction ) . Any surgical medical condition may interfere conduct study , may jeopardize subject case participation study may significantly alter absorption , distribution , metabolism excretion drug . History immunocompromise , include positive HIV test result ( ELISA Western blot ) . A HIV test require ; however , previous medical history review Female subject pregnant ( positive pregnancy test screen baseline ) lactating , childbearing potential practicing medically acceptable method birth control . Exclusion Criteria cohort 1 : Clinical evidence liver disease liver injury indicate abnormal liver function test . A positive Hepatitis B surface antigen ( HBsAg ) Hepatitis C test result ( antibody positive subject allow nonviremic ) . Exclusion Criteria cohort 24 : Symptoms history encephalopathy ( Stage III worse ) within three month prior dose . Clinical evidence severe ascites .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Pasireotide</keyword>
	<keyword>PK profile ,</keyword>
	<keyword>Single dose</keyword>
	<keyword>Pasireotide subcutaneous injection</keyword>
	<keyword>Safety</keyword>
	<keyword>Mild hepatic impair patient</keyword>
	<keyword>Moderate hepatic impair patient</keyword>
	<keyword>Severe hepatic impair patient</keyword>
</DOC>